TCDD induced pericardial edema and relative COX-2 expression in medaka (Oryzias Latipes) embryos.
Exposure to dioxin and other aryl hydrocarbon receptor (AhR) ligands results in multiple, specific developmental cardiovascular phenotypes including pericardial edema and circulatory failure in small aquarium fish models. Although phenotypes are well described, mechanistic underpinnings for such toxicities remain elusive. Here we suggest that AhR activation results in stimulation of inflammation and "eicosanoid" pathways, which contribute to the observed developmental, cardiovascular phenotypes. We demonstrate that medaka embryos exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (0.05-1 ppb) during early development result in a dose-related increase in the prevalence of pericardial edema and that this phenotype correlates with an increase in cyclooxygenase-2 (COX-2) gene expression. Those individuals exhibiting the edema phenotype had significantly greater COX-2 mRNA than their nonedematous cohort. Selective pharmacological inhibition of COX-2, with NS-398, and genetic knock down of COX-2 with a translation initiation morpholino significantly attenuated prevalence and severity of edema phenotype. Subsequently, exposures of medaka embryos to arachidonic acid (AA) resulted in recapitulation of the pericardial edema phenotype and significantly increased COX-2 expression only in those individuals exhibiting the edema phenotype compared with their nonedematous cohort. AA exposure does not result in significant induction of cytochrome P450 1A expression, suggesting that pericardial edema can be induced independent of AhR/aryl hydrocarbon receptor nuclear translocator/dioxin response element interactions. Results from this study demonstrate that developmental exposure to TCDD results in an induction of inflammatory mediators including COX-2, which contribute to the onset, and progression of heart dysmorphogenesis in the medaka model.
Dong
Wu
W
Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, North Carolina 27695, USA.
Matsumura
Fumio
F
Kullman
Seth W
SW
D000818:Animals; D016718:Arachidonic Acid / Q000494:pharmacology; D051546:Cyclooxygenase 2 / Q000096:biosynthesis* / Q000235:genetics; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004625:Embryo, Nonmammalian / Q000002:abnormalities / Q000187:drug effects* / Q000201:enzymology; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D020868:Gene Silencing; D009578:Nitrobenzenes / Q000494:pharmacology; D009990:Oryzias / Q000502:physiology*; D010490:Pericardial Effusion / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D000072317:Polychlorinated Dibenzodioxins / Q000633:toxicity*; D012333:RNA, Messenger / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D013723:Teratogens / Q000633:toxicity*
D016861:Cyclooxygenase Inhibitors; D009578:Nitrobenzenes; D000072317:Polychlorinated Dibenzodioxins; D012333:RNA, Messenger; D013449:Sulfonamides; D013723:Teratogens; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D016718:Arachidonic Acid; D051546:Cyclooxygenase 2
Biochem Pharmacol. 2009 Feb 15;77(4):608-26
18996358
Biochemistry. 2008 Dec 30;47(52):13997-4008
19063610
Toxicol Sci. 2005 May;85(1):572-84
15703262
Toxicol Sci. 2005 Apr;84(2):328-34
15673847
Mech Dev. 2004 Jul;121(7-8):605-18
15210170
J Immunol. 2006 Sep 15;177(6):3635-43
16951323
Toxicol Appl Pharmacol. 2009 Jan 1;234(1):33-40
18952116
Toxicol Sci. 1999 Jan;47(1):40-51
10048152
J Biol Chem. 1993 Oct 15;268(29):21931-8
8408049
Annu Rev Pharmacol Toxicol. 1998;38:97-120
9597150
Dev Comp Immunol. 2004 Jan;28(1):9-28
12962979
Mol Pharmacol. 2006 Aug;70(2):549-61
16714409
J Mol Cell Cardiol. 2006 May;40(5):688-95
16499924
Biochem Pharmacol. 2010 Feb 1;79(3):487-97
19782052
Toxicol Appl Pharmacol. 2000 Sep 15;167(3):210-21
10986012
Development. 2008 Mar;135(6):1179-87
18272595
Cardiovasc Res. 2009 May 1;82(2):240-9
19074824
Biochem Pharmacol. 1997 Dec 15;54(12):1287-96
9393671
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:177-85
12432917
Cardiovasc Pathol. 2007 Sep-Oct;16(5):300-4
17868881
J Cell Mol Med. 2009 Sep;13(9B):3753-63
18657230
Toxicol Appl Pharmacol. 2008 Dec 1;233(2):333-42
18840457
J Leukoc Biol. 2007 Jan;81(1):263-71
17046968
Mar Pollut Bull. 2008;57(6-12):255-66
18433798
Toxicol Sci. 2008 Feb;101(2):321-30
17975115
Annu Rev Biochem. 2000;69:145-82
10966456
Cardiovasc Toxicol. 2007;7(4):264-72
17955387
Toxicol Appl Pharmacol. 2008 Sep 15;231(3):374-83
18606429
J Biol Chem. 2004 Aug 20;279(34):35403-11
15213229
Toxicol Sci. 2007 Dec;100(2):486-94
17823451
Mol Pharmacol. 2008 Jul;74(1):255-63
18388244
Mol Endocrinol. 2009 Apr;23(4):549-58
19147701
Chemosphere. 2009 Mar;74(11):1531-7
19162293
Cardiovasc Hematol Agents Med Chem. 2008 Jan;6(1):69-79
18220723
Curr Biol. 2004 Feb 17;14(4):R152-3
15027466
Toxicol Sci. 2003 Nov;76(1):138-50
12883077
Birth Defects Res A Clin Mol Teratol. 2006 Jan;76(1):7-18
16333842
Anat Rec. 2002 Jun 1;267(2):137-45
11997882
J Nutr. 2009 Jan;139(1):26-32
19056653
Biol Pharm Bull. 2002 Sep;25(9):1165-8
12230110
Dev Biol. 2010 Apr 1;340(1):30-40
20096279
Mol Pharmacol. 2006 Mar;69(3):776-87
16306231
Toxicol Sci. 2008 Nov;106(1):193-205
18660518
Toxicol Sci. 2006 Nov;94(1):175-82
16936225
Bull Environ Contam Toxicol. 1999 Oct;63(4):423-9
10501717
Cardiovasc Toxicol. 2004;4(4):363-73
15531779
J Cell Biochem. 2007 Dec 15;102(6):1486-92
17471498
Toxicol Sci. 2005 Apr;84(2):368-77
15635151
Am J Physiol Heart Circ Physiol. 2010 Jan;298(1):H136-43
19880670
Methods. 2001 Dec;25(4):402-8
11846609
Teratology. 2001 Oct;64(4):201-12
11598926
J Am Coll Cardiol. 2007 Oct 16;50(16):1590-5
17936159
Toxicol Sci. 2008 Aug;104(2):303-11
18477685
Toxicol Appl Pharmacol. 2007 Jun 15;221(3):285-94
17482227
PLoS Biol. 2007 Mar;5(3):e53
17311471
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Oct;27(4):276-85
19953399
Toxicol Sci. 2005 Feb;83(2):397-404
15525691
Am J Respir Cell Mol Biol. 2010 Feb;42(2):210-7
19372248